Skip to content
Search

Latest Stories

MHRA recalls Sildenafil 100mg film-coated tablets

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 3 medicines recall for Sildenafil 100mg Film-coated Tablets (Strandhaven Limited T/A Somex Pharma).

Manufacturer of drug, Strandhaven Limited T/A Somex Pharma has informed the MHRA that the pack size on some cartons of the batch state 8 tablets instead of 4 tablets. This is an error due to cartons being mixed at the printers. All cartons with batch number ET22028 contain one blister strip of 4 tablets regardless of whether it states 8 tablets or 4 tablets on the pack.


Only the batch number ET22028 is affected. Due to the low number of complaints received, only the packs labelled as containing 8 tablets are being recalled at this time. The batch is comprised of 60340 packs, to date 195 packs have been found to be mislabelled.

The quality and safety of the tablets is not impacted and therefore this is not a patient level recall.

Strandhaven Limited T/A Somex Pharma ask that healthcare professionals stop supplying and quarantine any stock with this batch number that is labelled as containing 8 tablets. Return these packs through your approved process.

The packs labelled as 4 tablets, can be dispensed as normal. The quality and safety of the tablets is not impacted and therefore this is not a patient level recall.

For Patients that were already prescribed 8 tablets and have received one pack of this batch (the patient will have received only 4 tablets).

SNOMED Code: 326715008

Batch NoExpiry DatePack SizeFirst Distributed
ET2202802/20254 tablets*16.01.2023

*Mislabelled packs indicate 8 tablets

More For You

Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less
Three pharmacists named in NIHR’s latest cohort of senior investigators

L-R: Professor David Alldred; Professor Rachel Elliott and Professor Ian Maidment.

Three pharmacists appointed as NIHR senior investigators

The National Institute for Health and Care Research (NIHR) has announced its latest cohort of senior investigators, including three distinguished pharmacists.

David Alldred, professor of medicines use and safety at the University of Leeds; Rachel Elliott, professor of health economics at the University of Manchester; and Ian Maidment, professor in clinical pharmacy at Aston University, have been named in the list of 39 new appointments, alongside 19 reappointed senior investigators.

Keep ReadingShow less
Vaccine-preventable infections costing UK billions

Effective interventions are needed to prevent hospitalisations

Vaccine-preventable infections costing UK billions

Effective interventions are having a positive impact but more needs to be done to combat vaccine-preventable infections after data revealed today showed that it accounted for 20 per cent of hospital bed usage in the UK between 2023 to 2024 at a cost of almost £6 billion.

The return of social mixing, international travel and migration following the COVID-19 pandemic have contributed to the rise in both endemic disease and vaccine-preventable infections, according to the UK Health Security Agency's (UKHSA).

Keep ReadingShow less